Estimation, power and sample size calculations for stochastic cost and effectiveness analysis

PharmacoEconomics

Volumn 25, Issue 6, 2007, Pages 455-466

  Walter, S D ^a   Gafni, Amiram ^a,b   Birch, Stephen ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH PROGRAM; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; PROBABILITY; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICS;

ALGORITHMS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; SAMPLE SIZE; STOCHASTIC PROCESSES;

EID: 34249803854     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725060-00002     Document Type: Article

References (19)

1. Gardiner J, Huebner M, Jeton J, et al. Power and sample size assessments for test hypotheses on cost-effectiveness ratios. Health Econ 2000; 9: 227-34
2. Backhouse ME. Use of randomized controlled trials for producing cost-effectiveness evidence. Pharmacoeconomics 2002; 20: 1061-77
3. Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Dec Making 1998; 18 Suppl.: S81-92
4. Willan A, O'Brien B. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999; 8: 203-11
5. Fieller EC. Some problems in interval estimation. J Royal Statist Soc, Series B, 1954; 16: 175-83
6. Laska E, Meisner M, Siegel C. Power and sample size in cost-effectiveness analysis. Med Dec Making 1999; 19: 339-43
7. Al M, Van Hout B, Michel B, et al. Sample size calculations in economic evaluations. Health Econ 1998; 7: 327-35
8. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost effectiveness analysis. Health Econ 2002; 11: 415-30
9. Briggs AH, O'Brien BJ, Blackhause G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Am Rev Public Health 2002; 23: 377-401
10. Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ 2002; 11: 185-91
11. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should 'reasonable decisions' lead to uncontrolled growth in expenditures? Can Med Assoc J 2003; 168: 849-51
12. Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluations of health care programs. Health Econ 2002; 11: 23-31
13. O'Brien B, Gertsen K, Willan A, et al. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ 2002; 11: 175-80
14. Cook RJ, Dunnett CW. Multiple comparisons. In: Armitage P, Colton T, editors. Encyclopedia of biostatistics. New York: Wiley, 1999: 2736-46
15. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 1967; 62: 626-33
16. Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243-52
17. Birch S, Gafni A. Cost effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279-96
18. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis)application of economics to real world problems. J Health Econ 1993; 12: 469-76
19. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18 (3): 341-64